J.L. Mansi , D. Easton , U. Berger , J.-C. Gazet , H.T. Ford , D. Dearnaley , R.C. Coombes
{"title":"原发性乳腺癌骨髓微转移:6年随访后的预后意义","authors":"J.L. Mansi , D. Easton , U. Berger , J.-C. Gazet , H.T. Ford , D. Dearnaley , R.C. Coombes","doi":"10.1016/0277-5379(91)90413-8","DOIUrl":null,"url":null,"abstract":"<div><p>Using an antiserum to epithelial membrane antigen we have screened multiple bone marrow aspirates from 350 patients with primary breast cancer taken at the time of initial surgery. 89 (25%) patients were found to have micrometastases and their presence was related to pathological size (<em>P</em> < 0.01), the presence of peritumoral vascular invasion (<em>P</em> < 0.001), and positive lymph nodes (<em>P</em> < 0.005) but not menopausal status. At a median follow-up of 76 months (range 34–108) 107 patients had relapsed with distant metastases. 48% (43 of 89) of these patients had micrometastases initially compared with 25% (64 of 261) who did not (<em>P</em> < 0.005). The test predicts for relapse in bone (<em>P</em> < 0.01) and other distant sites excluding bone (<em>P</em> < 0.001) and is associated with a shorter overall survival (<em>P</em> < 0.005). We conclude that the detection of micrometastases signals a high likelihood of early relapse and decreased survival in breast cancer.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 12","pages":"Pages 1552-1555"},"PeriodicalIF":0.0000,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90413-8","citationCount":"201","resultStr":"{\"title\":\"Bone marrow micrometastases in primary breast cancer: Prognostic significance after 6 years' follow-up\",\"authors\":\"J.L. Mansi , D. Easton , U. Berger , J.-C. Gazet , H.T. Ford , D. Dearnaley , R.C. Coombes\",\"doi\":\"10.1016/0277-5379(91)90413-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Using an antiserum to epithelial membrane antigen we have screened multiple bone marrow aspirates from 350 patients with primary breast cancer taken at the time of initial surgery. 89 (25%) patients were found to have micrometastases and their presence was related to pathological size (<em>P</em> < 0.01), the presence of peritumoral vascular invasion (<em>P</em> < 0.001), and positive lymph nodes (<em>P</em> < 0.005) but not menopausal status. At a median follow-up of 76 months (range 34–108) 107 patients had relapsed with distant metastases. 48% (43 of 89) of these patients had micrometastases initially compared with 25% (64 of 261) who did not (<em>P</em> < 0.005). The test predicts for relapse in bone (<em>P</em> < 0.01) and other distant sites excluding bone (<em>P</em> < 0.001) and is associated with a shorter overall survival (<em>P</em> < 0.005). We conclude that the detection of micrometastases signals a high likelihood of early relapse and decreased survival in breast cancer.</p></div>\",\"PeriodicalId\":11925,\"journal\":{\"name\":\"European Journal of Cancer and Clinical Oncology\",\"volume\":\"27 12\",\"pages\":\"Pages 1552-1555\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1991-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/0277-5379(91)90413-8\",\"citationCount\":\"201\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Cancer and Clinical Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/0277537991904138\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer and Clinical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/0277537991904138","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Bone marrow micrometastases in primary breast cancer: Prognostic significance after 6 years' follow-up
Using an antiserum to epithelial membrane antigen we have screened multiple bone marrow aspirates from 350 patients with primary breast cancer taken at the time of initial surgery. 89 (25%) patients were found to have micrometastases and their presence was related to pathological size (P < 0.01), the presence of peritumoral vascular invasion (P < 0.001), and positive lymph nodes (P < 0.005) but not menopausal status. At a median follow-up of 76 months (range 34–108) 107 patients had relapsed with distant metastases. 48% (43 of 89) of these patients had micrometastases initially compared with 25% (64 of 261) who did not (P < 0.005). The test predicts for relapse in bone (P < 0.01) and other distant sites excluding bone (P < 0.001) and is associated with a shorter overall survival (P < 0.005). We conclude that the detection of micrometastases signals a high likelihood of early relapse and decreased survival in breast cancer.